AZ's Dapagliflozin Impresses In Topline Phase III Heart Failure Study
AstraZeneca’s SGLT2 inhibitor has grabbed attention for its potential role in chronic heart failure patients, with or without type 2 diabetes, following initial results from the DAPA-HF study.
You may also be interested in...
A Phase III trial in heart failure with preserved ejection fraction showed a benefit, which could result in a broad heart failure label for the SGLT2 inhibitor.
Entresto has narrowly failed to hit the primary endpoint in a Phase III trial in heart failure with preserved ejection fraction, a potentially lucrative indication with no approved treatments.
The German major believes its drug will remain the biggest-selling SGLT-2 inhibitor boosted by expanded heart and renal disease approvals.